Related Experiment Video
Updated: Oct 1, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Bihormonal fully closed-loop glucose control in adolescents with Type 1 diabetes: an outpatient, randomized,
Richell S Booijink1, Job S de Haan1, Loes Van Den Berg1
1Inreda Diabetic, 7472 DD Goor, the Netherlands.
Abstract:
Effective diabetes management in adolescents with Type 1 diabetes is crucial to reduce the risk of long-term complications. However, adolescents show the poorest glycemic outcomes of all age groups. A bihormonal fully closed-loop (FCL) system, which requires no user input, may help address these challenges. In this trial, the performance and safety of a bihormonal FCL system (Inreda® AP) was evaluated in adolescents. The trial was a single-center, randomized, crossover trial in adolescents with Type 1 diabetes aged 12-18 years. The FCL system was compared with the participants' usual diabetes treatment in a home healthcare setting. The trial consisted of two study periods of 2 weeks, separated by a 2-week washout period. The primary endpoint was time in range (TIR; 3.9-10.0 mmol/L). In total, 20 individuals were enrolled and the data from 15 of them were analyzed. Glucose outcome parameters showed significant improvements during the FCL treatment period. Median TIR was 61.3% [interquartile range (IQR): 53.7%-68.2%] in the control period compared with 74.9% (IQR: 73.1-81.0) during the FCL period (p < 0.001). Additionally, other glucose outcomes including time above range (> 10.0 mmol/L) and median blood glucose were significantly improved in the FCL treatment period. To conclude, this trial provides preliminary evidence that treatment with the bihormonal FCL system may improve glucose outcome parameters, with no safety concerns observed in adolescents with Type 1 diabetes over the short study duration. However, future research should focus on long-term trials with larger study populations to confirm these findings and evaluate the long-term effects of bihormonal FCL treatment in adolescents.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Hypoglycemia
Hyperglycemia